Omacor

DRUG8 trials

Conditions

AtherosclerosisChronic Heart FailureHyper-TriglyceridemiaHyperlipidemia, HypertriglyceridemiaKidney TransplantationNon Alcoholic Fatty Liver DiseaseNon-Alcoholic Fatty Liver DiseasePeripheral Arterial Disease

Phase 1

Phase I Drug-drug Interaction of Omega-3 and Atorvastatin

NCT03438955

DongKoo Bio & PharmaHyperlipidemia, Hypertriglyceridemia

Start: 2018-02-01End: 2018-08-31Target: 48Updated: 2018-02-22

Phase 2

Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure

CompletedNCT00149409

Medical University of ViennaChronic Heart Failure

Start: 2005-09-30End: 2008-02-29Updated: 2010-07-13

Phase 3

The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease

CompletedNCT01277237

University of EdinburghNon Alcoholic Fatty Liver Disease

Start: 2010-09-30End: 2012-08-31Updated: 2014-01-23

OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease

CompletedNCT01367145

Medical University of ViennaPeripheral Arterial Disease

Start: 2011-01-31End: 2014-03-31Updated: 2014-08-26

The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation

CompletedNCT03018041

Joe ChanKidney Transplantation

Start: 2017-09-01End: 2025-03-22Updated: 2025-04-03

Phase 4

Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

CompletedNCT00328536

Ruhr University of BochumAtherosclerosis, Type 2 Diabetes Mellitus

Start: 2007-04-30End: 2008-11-30Target: 34Updated: 2009-05-08

Effect of Omacor on Triglycerides in HIV Infected Subjects

TerminatedNCT00598910

Solvay PharmaceuticalsHyper-Triglyceridemia

Start: 2007-08-31End: 2009-03-31Updated: 2009-03-30

Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids

CompletedNCT00760513

University Hospital Southampton NHS Foundation TrustNon-Alcoholic Fatty Liver Disease

Start: 2009-11-01End: 2018-11-29Updated: 2019-10-25

2021-10-048 citations

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.

2016-04-229 citations

Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.

2015-12-2444 citations

Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.

2015-05-2917 citations

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].

2014-02-1840 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Circulating Adiponectin and Leptin in Subjects with Type 2 Diabetes Mellitus

Hormone and Metabolic Research2013-12-1922 citations